{"id":70754,"date":"2026-05-12T10:43:33","date_gmt":"2026-05-12T10:43:33","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70754"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"mazdutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ja\/product\/mazdutide\/","title":{"rendered":"Mazdutide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">\u30af\u30a4\u30c3\u30af\u30a2\u30f3\u30b5\u30fc \u2014 Mazdutide\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p style=\"margin: 0;\"><strong>Mazdutide<\/strong> (developmental codes IBI362 \/ LY3305677) is a long-acting dual GLP-1 and glucagon receptor co-agonist peptide developed by Innovent Biologics (in-licensed from Eli Lilly). It is the first dual GLP-1\/glucagon agonist to reach Phase 3 trials in obesity and type 2 diabetes, with the glucagon component adding an energy-expenditure mechanism beyond what GLP-1-only and GLP-1\/GIP-dual peptides produce. Plasma half-life supports once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>MedsBase\u3067\u5f97\u3089\u308c\u308b\u3082\u306e\uff1a<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/ja\/reviews\/\">\u30ab\u30b9\u30bf\u30de\u30fc\u30ec\u30d3\u30e5\u30fc<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 \u3059\u3079\u3066\u306e\u3054\u6ce8\u6587\u306f\u3001\u5f53\u5e97\u306e <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\"><strong>\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/strong><\/a> \u2014 \u4e07\u304c\u4e00\u300120\u55b6\u696d\u65e5\u4ee5\u5185\u306b\u5546\u54c1\u304c\u5c4a\u304b\u306a\u3044\u5834\u5408\u306f\u3001\u518d\u767a\u9001\u3044\u305f\u3057\u307e\u3059\u3002<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">\u4ed5\u69d8<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">\u8a73\u7d30<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS\u756a\u53f7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2376247-09-1\uff08mazdutide\uff1b\u4e00\u822c\u7684\u306b\u5f15\u7528\u3055\u308c\u308b\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u30bf\u30a4\u30d7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9577\u6642\u9593\u4f5c\u7528\u578b\u30c7\u30e5\u30a2\u30ebGLP-1\/\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u5171\u4f5c\u7528\u85ac\uff08\u30a2\u30b7\u30eb\u5316\u5408\u6210\u30da\u30d7\u30c1\u30c9\uff1bInnovent IBI362 \/ Eli Lilly LY3305677\uff1b\u30aa\u30ad\u30b7\u30f3\u30c8\u30e2\u30b8\u30e5\u30ea\u30f3\u7531\u6765\u9aa8\u683c\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u7d044,865 Da\uff08\u8102\u80aa\u9178\u30a2\u30b7\u30eb\u5316\u3092\u542b\u3080\uff1b\u516c\u8868\u6210\u719f\u578b\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u69cb\u9020<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u5929\u7136\u306e\u30aa\u30ad\u30b7\u30f3\u30c8\u30e2\u30b8\u30e5\u30ea\u30f3\u9aa8\u683c\uff08\u5185\u56e0\u6027\u30c7\u30e5\u30a2\u30ebGLP-1\/\u30b0\u30eb\u30ab\u30b4\u30f3\u4f5c\u52d5\u85ac\uff09\u3092\u57fa\u306b\u3057\u305f\u5408\u6210\u30da\u30d7\u30c1\u30c9\u3067\u3042\u308a\u3001DPP-4\u8010\u6027\u3092\u4ed8\u4e0e\u3059\u308b\u6539\u5909\u7f6e\u63db\u3068\u3001\u30ea\u30b7\u30f3\u6b8b\u57fa\u306b\u03b3-Glu\u30ea\u30f3\u30ab\u30fc\u3092\u4ecb\u3057\u3066\u7d50\u5408\u3057\u305f\u8102\u80aa\u9178\u4e8c\u9178\u30a2\u30b7\u30eb\u30c6\u30b6\u30fc\u3092\u5099\u3048\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u30a2\u30b7\u30eb\u9396\u304c\u53ef\u9006\u7684\u306a\u8840\u6e05\u30a2\u30eb\u30d6\u30df\u30f3\u7d50\u5408\u3092\u4fc3\u9032\u3057\u3001\u90311\u56de\u6295\u4e0e\u3092\u53ef\u80fd\u306b\u3059\u308b\u8840\u4e2d\u534a\u6e1b\u671f\u306e\u5ef6\u9577\u3092\u3082\u305f\u3089\u3057\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5f62\u614b<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\uff08\u767d\u8272\u301c\u5fae\u9ec4\u8272\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u7d14\u5ea6<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599%\uff08HPLC\u691c\u8a3c\u6e08\u307f\u3001COA\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066\u63d0\u4f9b\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u4fdd\u7ba1\u65b9\u6cd5<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u54c1\uff1a\u4f7f\u7528\u6642\u5728\u5eab\u306f2\uff5e8\u2103\uff08\u51b7\u8535\uff09\u306b\u4fdd\u7ba1\u3002\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u7ba1\u306b\u306f\u221220\u2103\u3002\u518d\u6eb6\u89e3\u5f8c\uff1a2\uff5e8\u2103\u3067\u7d0430\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3002\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u6db2\u306e\u51cd\u7d50\u878d\u89e3\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u6eb6\u89e3\u6027<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9759\u83cc\u6c34\uff08\u63a8\u5968\uff09\u307e\u305f\u306f\u77ed\u671f\u9593\u4f7f\u7528\u306e\u5834\u5408\u306f\u6ec5\u83cc\u6c34\u3002\u30a2\u30b7\u30eb\u5316\u30da\u30d7\u30c1\u30c9\u306f\u6eb6\u89e3\u306b\u6642\u9593\u304c\u304b\u304b\u308b\u5834\u5408\u304c\u3042\u308a\u307e\u3059 \u2014 \u5341\u5206\u306a\u5e73\u8861\u5316\u6642\u9593\u3092\u53d6\u3063\u3066\u304f\u3060\u3055\u3044\u3002<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Mazdutide\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h2>\n<p><strong>Mazdutide<\/strong> is a long-acting synthetic dual GLP-1 and glucagon receptor co-agonist developed under the developmental codes IBI362 (Innovent Biologics, in-licensed from Eli Lilly LY3305677). It is one of the most advanced compounds in the renewed wave of oxyntomodulin-derived dual-agonist pharmacology \u2014 an approach distinct from both the GLP-1-only programme (semaglutide) and the GLP-1\/GIP dual-agonist programme (tirzepatide). The structural inspiration is oxyntomodulin itself, a 37-amino-acid product of preproglucagon processing in intestinal L-cells that natively activates both the GLP-1 and glucagon receptors. Endogenous oxyntomodulin has very short pharmacokinetics; mazdutide engineers around this with a fatty-acid acyl tether at a lysine residue that drives reversible serum-albumin binding and extends the plasma half-life sufficiently for once-weekly subcutaneous administration in clinical studies. Mazdutide has a mature molecular weight of approximately 4,865\u00a0Da including the acyl modification. The structural scaffold preserves the dual-receptor pharmacology of oxyntomodulin while engineered substitutions confer resistance to DPP-4-mediated proteolytic cleavage that would otherwise produce rapid clearance. Mazdutide is the lead Chinese metabolic peptide programme, with Phase 3 trials (GLORY-1 in obesity, DREAMS-1 and DREAMS-2 in type 2 diabetes) reporting body-weight reductions of approximately 15\u201317% at the highest dose tier over 48 weeks. Outside China, mazdutide is <strong>\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u305b\u3093<\/strong> by the FDA, EMA, MHRA, or any other major Western regulator. In China, mazdutide has been approved by the NMPA under its initial commercial brand \u2014 making it one of the first dual-agonist incretin peptides to receive regulatory clearance for human use anywhere. For the triple-agonist comparator that adds GIP on top of the same GLP-1\/glucagon combination, see our <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a> \u88fd\u54c1\u30da\u30fc\u30b8\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h2>\u4f5c\u7528\u6a5f\u5e8f \u2014 GLP-1\/\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u306e\u30c7\u30e5\u30a2\u30eb\u5171\u523a\u6fc0<\/h2>\n<p>\u30de\u30ba\u30c7\u30e5\u30c1\u30c9\u304c\u73fe\u5728\u306e\u30c7\u30e5\u30a2\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8\u4ee3\u8b1d\u30da\u30d7\u30c1\u30c9\u306e\u4e2d\u3067\u6a5f\u69cb\u7684\u306b\u969b\u7acb\u3063\u3066\u3044\u308b\u7406\u7531\u306f\u3001\u53e4\u5178\u7684\u306aGLP-1\u6e80\u8179\u611f\uff0f\u8840\u7cd6\u5236\u5fa1\u8ef8\u3068\u3001 <strong>\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u306e\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u8ef8<\/strong> \u2014 not the GIP receptor axis used by tirzepatide. The dual-receptor profile produces complementary effects across three principal compartments documented in published studies:<\/p>\n<ul>\n<li><strong>GLP-1\u53d7\u5bb9\u4f53\u6d3b\u6027\u5316 \u2014 \u6e80\u8179\u611f\u3001\u03b2\u7d30\u80de\u30a4\u30f3\u30b9\u30ea\u30f3\u5206\u6ccc\u3001\u80c3\u6392\u51fa<\/strong> \u2014 \u30de\u30ba\u30c7\u30e5\u30c1\u30c9\u306f\u3001\u81b5\u03b2\u7d30\u80de\u306eGLP-1\u53d7\u5bb9\u4f53\uff08\u30b0\u30eb\u30b3\u30fc\u30b9\u4f9d\u5b58\u6027\u30a4\u30f3\u30b9\u30ea\u30f3\u5206\u6ccc\uff09\u3001\u8996\u5e8a\u4e0b\u90e8\u5f13\u72b6\u6838\u306ePOMC\u30cb\u30e5\u30fc\u30ed\u30f3\uff08\u4e2d\u67a2\u6027\u6e80\u8179\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\uff09\u3001\u80c3\u8ff7\u8d70\u795e\u7d4c\u6c42\u5fc3\u6027\u7dda\u7dad\uff08\u80c3\u5185\u5bb9\u6392\u51fa\u9045\u5ef6\uff09\u3092\u6d3b\u6027\u5316\u3057\u307e\u3059\u3002\u3053\u306e\u4f5c\u7528\u306f\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u3084\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u3001\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9\u306eGLP-1\u6210\u5206\u306e\u30e1\u30ab\u30cb\u30ba\u30e0\u3068\u91cd\u306a\u308a\u307e\u3059\u3002<\/li>\n<li><strong>\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u306e\u6d3b\u6027\u5316 \u2014 \u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u3001\u809d\u8102\u8cea\u52d5\u54e1\u3001\u8910\u8272\u8102\u80aa\u7d44\u7e54\u306e\u6d3b\u6027\u5316<\/strong> \u2014 The defining feature of mazdutide is the simultaneous activation of the glucagon receptor. Glucagon-receptor agonism increases resting energy expenditure modestly, drives hepatic fatty-acid oxidation and lipid mobilisation from steatotic liver, and contributes to brown adipose tissue activation in published rodent studies. The energy-expenditure component is what distinguishes glucagon-containing multi-agonists (mazdutide, retatrutide, survodutide) from the body-weight effect of GLP-1-only and GLP-1\/GIP-dual peptides \u2014 the latter produce weight loss almost entirely through reduced energy intake, while glucagon-containing agonists add a metabolic-rate component.<\/li>\n<li><strong>\u53d7\u5bb9\u4f53\u6d3b\u6027\u306e\u30d0\u30e9\u30f3\u30b9\u3068\u300c\u30b0\u30eb\u30ab\u30b4\u30f3\u306e\u30d1\u30e9\u30c9\u30c3\u30af\u30b9\u300d\u201c<\/strong> \u2014 \u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u5171\u523a\u6fc0\u306b\u304a\u3051\u308b\u85ac\u7406\u5b66\u7684\u8ab2\u984c\u306f\u3001\u6709\u76ca\u306a\u6b63\u5473\u52b9\u679c\u3092\u9054\u6210\u3059\u308b\u3053\u3068\u3067\u3059\u3002\u30b0\u30eb\u30ab\u30b4\u30f3\u5358\u72ec\u3067\u306f\u809d\u81d3\u306e\u30b0\u30eb\u30b3\u30fc\u30b9\u51fa\u529b\u3092\u523a\u6fc0\u3057\u3066\u8840\u7cd6\u5024\u3092\u4e0a\u6607\u3055\u305b\u3001\u8840\u7cd6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3092\u60aa\u5316\u3055\u305b\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u30de\u30ba\u30c7\u30e5\u30c1\u30c9\u306eGLP-1\u6210\u5206\u306f\u3001\u03b2\u7d30\u80de\u3068\u03b1\u7d30\u80de\u3067\u306e\u30a4\u30f3\u30b9\u30ea\u30f3\u5206\u6ccc\u4fc3\u9032\u3068\u30b0\u30eb\u30ab\u30b4\u30f3\u6291\u5236\u306b\u3088\u308b\u5f37\u529b\u306a\u8840\u7cd6\u964d\u4e0b\u4f5c\u7528\u306b\u3088\u308a\u3001\u30b0\u30eb\u30ab\u30b4\u30f3\u306b\u3088\u308b\u8840\u7cd6\u4e0a\u6607\u52b9\u679c\u3092\u4e0a\u56de\u308a\u3001\u30b0\u30eb\u30ab\u30b4\u30f3\u4f5c\u7528\u306f\u8102\u8cea\u52d5\u54e1\u3068\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u306e\u5229\u70b9\u3092\u4fdd\u6301\u3057\u307e\u3059\u3002GLP-1\u5bfe\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u306e\u76f8\u5bfe\u7684\u306a\u52b9\u529b\u306f\u3001\u8840\u7cd6\u964d\u4e0b\u6b63\u5473\u52b9\u679c\u3092\u512a\u5148\u3059\u308b\u3088\u3046\u306b\u8a2d\u8a08\u3055\u308c\u3066\u304a\u308a\u3001\u2014 \u3053\u308c\u306f\u3001\u4ee5\u4e0b\u306e\u3088\u3046\u306a <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9<\/a> GIP\u3082\u5bc4\u4e0e\u3059\u308b\u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8.<\/li>\n<\/ul>\n<p>The fatty-acid acyl tether attached at a lysine residue binds reversibly to circulating serum albumin, producing a plasma depot that extends the effective half-life to support once-weekly subcutaneous dosing in clinical studies. Subcutaneous administration is the standard administration route. The mechanism for sustained-release distribution is analogous to semaglutide&#8217;s C18 and tirzepatide&#8217;s C20 fatty-acid systems but with different chain length and linker chemistry tuned to mazdutide&#8217;s dual-receptor pharmacology. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Mazdutide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 preclinical DIO rodent models, body-composition (DEXA\/MRI), food-intake assays, respiratory exchange ratio and resting energy expenditure; canonical dual GLP-1\/glucagon peptide<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 \u8840\u7cd6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3001HbA1c\u4ee3\u66ff\u6307\u6a19\u3001\u30b0\u30eb\u30ab\u30b4\u30f3\u6291\u5236\u52d5\u614b\u3001\u9ad8\u8102\u80aa\u98df\u304a\u3088\u3073db\/db\u3052\u3063\u6b6f\u985e\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\u30a4\u30f3\u30b9\u30ea\u30f3\u611f\u53d7\u6027\uff1bGLP-1\u5358\u72ec\u4f5c\u52d5\u85ac\u304a\u3088\u3073GLP-1\/GIP\u4e8c\u91cd\u4f5c\u52d5\u85ac\u3068\u306e\u76f4\u63a5\u6bd4\u8f03<\/li>\n<li><strong>MASLD\/MASH\uff08\u4ee3\u8b1d\u6a5f\u80fd\u969c\u5bb3\u95a2\u9023\u809d\u75be\u60a3\uff09<\/strong> \u2014 \u809d\u81d3\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u542b\u91cf\u3001ALT\/AST\u3001\u7dda\u7dad\u5316\u30b9\u30c6\u30fc\u30b8\u5206\u985e\uff1b\u8102\u80aa\u809d\u306b\u304a\u3051\u308b\u30b0\u30eb\u30ab\u30b4\u30f3\u6210\u5206\u306e\u8102\u8cea\u52d5\u54e1\u4f5c\u7528\u306b\u3088\u308b\u7279\u7570\u7684\u306a\u95a2\u5fc3<\/li>\n<li><strong>Energy-expenditure studies<\/strong> \u2014 \u5b89\u9759\u6642\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u91cf\u6e2c\u5b9a\u3001\u8910\u8272\u8102\u80aa\u7d44\u7e54\u6d3b\u6027\u5316\u3001\u71b1\u7523\u751f\u907a\u4f1d\u5b50\u767a\u73fe\uff1b\u30b0\u30eb\u30ab\u30b4\u30f3\u99c6\u52d5\u6027\u4ee3\u8b1d\u7387\u8981\u7d20\u306e\u30e1\u30ab\u30cb\u30ba\u30e0\u89e3\u660e<\/li>\n<li><strong>Comparative dual-agonist studies<\/strong> \u2014 \u4ee3\u66ff\u4e8c\u91cd\u4f5c\u52d5\u85ac\u3068\u306e\u76f4\u63a5\u6bd4\u8f03 <a href=\"https:\/\/medsbase.com\/ja\/tirzepatide\/\">\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/a> (GLP-1\/GIP) \u304a\u3088\u3073\u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8 <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a> (GLP-1\/GIP\/glucagon); receptor-stacking strategy studies<\/li>\n<li><strong>Cardiovascular and renal studies<\/strong> \u2014 \u8840\u5727\u3001\u8102\u8cea\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3001ApoE\u306b\u304a\u3051\u308b\u52d5\u8108\u786c\u5316\u9032\u884c\u3078\u306e\u5f71\u97ff<sup>-\/-<\/sup> \u30e2\u30c7\u30eb\uff1b\u30de\u30ba\u30c7\u30e5\u30bf\u30a4\u30c9\u306e\u7b2c3\u76f8\u6210\u719f\u6bb5\u968e\u306b\u304a\u3051\u308b\u65b0\u305f\u306a\u30c7\u30fc\u30bf\u30bb\u30c3\u30c8<\/li>\n<li><strong>\u30b0\u30eb\u30ab\u30b4\u30f3\u8ef8\u306e\u85ac\u7406\u5b66<\/strong> \u2014 \u5358\u96e2\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u306e\u85ac\u7406\u5b66\u7684\u7279\u6027\u8a55\u4fa1\u3001\u809d\u81d3\u306e\u30b0\u30eb\u30b3\u30fc\u30b9\u7523\u751f\u52d5\u614b\u3001\u4e8c\u91cd\u4f5c\u52d5\u85ac\u5206\u5b50\u306b\u304a\u3051\u308b\u30b0\u30eb\u30ab\u30b4\u30f3\u6291\u5236\u3068\u30b0\u30eb\u30ab\u30b4\u30f3\u4f5c\u52d5\u6027\u306e\u30d0\u30e9\u30f3\u30b9<\/li>\n<li><strong>Comparative incretin studies<\/strong> \u2014 GLP-1\u5358\u72ec\u4f5c\u52d5\u85ac\u3068\u306e\u6bd4\u8f03\uff08<a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a>\uff09\u3001GLP-1\/GIP\u30c7\u30e5\u30a2\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8\uff08<a href=\"https:\/\/medsbase.com\/ja\/tirzepatide\/\">\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/a>\uff09\u3001\u306a\u3089\u3073\u306b\u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8GLP-1\/GIP\/\u30b0\u30eb\u30ab\u30b4\u30f3\uff08<a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a>).<\/li>\n<\/ul>\n<p>\u30de\u30ba\u30c7\u30e5\u30bf\u30a4\u30c9\u304c\u591a\u30a2\u30b4\u30cb\u30b9\u30c8\u4ee3\u8b1d\u30da\u30d7\u30c1\u30c9\u5206\u91ce\u306b\u304a\u3044\u3066\u3069\u306e\u3088\u3046\u306a\u4f4d\u7f6e\u3065\u3051\u306b\u3042\u308b\u304b\u306b\u3064\u3044\u3066\u306e\u3088\u308a\u5e83\u3044\u6587\u8108\u306b\u3064\u3044\u3066\u306f\u3001\u3054\u53c2\u7167\u304f\u3060\u3055\u3044\u3002 <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a> GIP\u3092\u8ffd\u52a0\u3059\u308b\u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8\u306e\u6bd4\u8f03\u5bfe\u8c61\u3068\u3057\u3066\u3001, <a href=\"https:\/\/medsbase.com\/ja\/tirzepatide\/\">\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/a> \u30b0\u30eb\u30ab\u30b4\u30f3\u3067\u306f\u306a\u304fGIP\u3092\u7528\u3044\u308b\u4ee3\u66ff\u306e\u30c7\u30e5\u30a2\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8\u3068\u3057\u3066\u3001, <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a> \u5358\u4e00\u30a2\u30b4\u30cb\u30b9\u30c8\u306e\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u3068\u3057\u3066\u3001\u304a\u3088\u3073 <a href=\"https:\/\/medsbase.com\/ja\/cagrilintide\/\">\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9<\/a> \u30a2\u30df\u30ea\u30f3\u8ef8\u306e\u4f75\u7528\u85ac\u7406\u5b66\u306e\u4ee3\u66ff\u3068\u3057\u3066\u3002\u5168\u4f53\u306e <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\">\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/a> \u5316\u5408\u7269\u9078\u629e\u306e\u305f\u3081\u306b\u3002 <\/p>\n<h2>\u5229\u7528\u53ef\u80fd\u306a\u529b\u4fa1\u3068\u6fc3\u5ea6<\/h2>\n<p>MedsBase stocks Mazdutide in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d0\u30a4\u30a2\u30eb\u529b\u4fa1<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u4ee3\u8868\u7684\u306a\u4f7f\u7528\u4f8b<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d1\u30c3\u30af\u30b5\u30a4\u30ba<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, single-cohort protocols, titration arms<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u9577\u671f\u30b5\u30a4\u30af\u30eb\u30d7\u30ed\u30c8\u30b3\u30eb\u3001\u591a\u30b3\u30db\u30fc\u30c8\u7814\u7a76\u30011mg\u3042\u305f\u308a\u6700\u5b89\u30b3\u30b9\u30c8<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 3 clinical doses are 4\u20139\u00a0mg weekly, so pharmaceutical-grade vials at 5\u00a0mg or 10\u00a0mg represent single-to-multi-week supplies of clinical-equivalent dosing for in-vivo work. Mazdutide is a comparatively scarce peptide because of structural complexity and active clinical development, which is reflected in the per-mg price relative to mature small synthetic peptides. <\/p>\n<h2>\u6bd4\u8f03\u65b9\u6cd5 \u2014 \u30de\u30ba\u30c7\u30e5\u30bf\u30a4\u30c9 vs \u30ec\u30bf\u30eb\u30c8\u30eb\u30c1\u30c9<\/h2>\n<p>\u30de\u30ba\u30c7\u30e5\u30bf\u30a4\u30c9\u3068 <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a> are the two canonical glucagon-receptor-containing multi-agonist metabolic peptides in current studies. They share the GLP-1 + glucagon backbone and differ in whether they also activate the GIP receptor \u2014 Retatrutide does (triple agonist), Mazdutide does not (dual agonist). The comparison is one of the cleanest in current metabolic-peptide pharmacology because the GLP-1 and glucagon arms are shared, isolating the contribution of the GIP component. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u8a55\u4fa1\u9805\u76ee<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Mazdutide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u53d7\u5bb9\u4f53\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glucagon\uff08\u30c7\u30e5\u30a2\u30eb\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + \u30b0\u30eb\u30ab\u30b4\u30f3\uff08\u4e09\u91cd\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u5206\u5b50\u9aa8\u683c<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30aa\u30ad\u30b7\u30f3\u30c8\u30e2\u30b8\u30e5\u30ea\u30f3\u7531\u6765<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GIP\u7531\u6765<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u30a2\u30df\u30ce\u9178\u6570<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d0439\u30a2\u30df\u30ce\u9178<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">39\u30a2\u30df\u30ce\u9178<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u534a\u6e1b\u671f<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u90311\u56de\uff08\u30a2\u30b7\u30eb\u5316\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d046\u65e5<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u958b\u767a\u5143\uff0f\u8d77\u6e90<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Innovent\uff08IBI362\uff09\uff0fEli Lilly\uff08LY3305677\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Eli Lilly\uff08LY3437943\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u627f\u8a8d\u72b6\u6cc1<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u4e2d\u56fd\u3067\u627f\u8a8d\uff08NMPA\uff09\u3001\u305d\u306e\u4ed6\u5730\u57df\u3067\u306f\u6cbb\u9a13\u6bb5\u968e<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u6cbb\u9a13\u6bb5\u968e\uff08\u7b2c3\u76f8\uff09<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4f53\u91cd\u52b9\u679c<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d0415\uff5e17%\uff08GLORY-1\u7b2c3\u76f8\u300148\u9031\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d0424%\uff08\u7b2c2\u76f8\u300148\u9031\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical studies weekly dose<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4\u20139 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u201312\u00a0mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The principal pharmacological question separating the two is the value of GIP receptor activation on top of GLP-1 + glucagon. Retatrutide&#8217;s Phase 2 body-weight effect is larger, suggesting GIP adds substantial benefit, but the more selective dual-agonist profile of mazdutide produces a potentially cleaner side-effect signal that may matter for long-term tolerability studies. For glucagon-axis-specific pharmacology, mazdutide is the cleaner tool because it isolates the GLP-1 + glucagon combination without the confound of GIP. For maximum-magnitude body-weight studies, the triple-agonist <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9<\/a> \u304c\u6a19\u6e96\u7684\u306a\u53c2\u7167\u57fa\u6e96\u3067\u3042\u308a\u7d9a\u3051\u3066\u3044\u307e\u3059\u3002 <\/p>\n<h2>\u4fdd\u7ba1\u65b9\u6cd5\u3068\u518d\u6eb6\u89e3<\/h2>\n<p><strong>\u518d\u6eb6\u89e3\u524d\uff1a<\/strong> \u77ed\u671f\u4f7f\u7528\u306e\u4f5c\u696d\u7528\u30b9\u30c8\u30c3\u30af\u3068\u3057\u3066\u3001\u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\u306f\u5143\u306e\u5305\u88c5\u306e\u307e\u307e2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u672a\u958b\u5c01\u306e\u9577\u671f\u4fdd\u5b58\u3067\u306f\u3001-20\u00b0C\u3067\u51b7\u51cd\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u4e7e\u71e5\u30de\u30ba\u30c7\u30e5\u30c1\u30c9\u306f\u51b7\u8535\u3067\u6700\u957724\u304b\u6708\u3001-20\u00b0C\u3067\u6700\u957736\u304b\u6708\u5b89\u5b9a\u3067\u3059\u3002\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\u306e\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002 <strong>\u518d\u6eb6\u89e3\u624b\u9806\uff1a<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers 100\u00a0mcg; 0.2\u00a0mL delivers 500\u00a0mcg; ~1.6\u00a0mL delivers a 4\u00a0mg clinical-equivalent dose. Swirl gently \u2014 do <strong>\u3057\u307e\u305b\u3093<\/strong> \u632f\u3068\u3046\u2014\u2014\u305d\u3057\u3066\u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30675\uff5e10\u5206\u9593\u9759\u7f6e\u3057\u307e\u3059\uff08\u30a2\u30b7\u30eb\u5316\u30da\u30d7\u30c1\u30c9\u306f\u5c0f\u3055\u306a\u975e\u4fee\u98fe\u30da\u30d7\u30c1\u30c9\u3088\u308a\u3082\u6eb6\u89e3\u304c\u9045\u3044\uff09\u3002\u9069\u5207\u306b\u518d\u69cb\u6210\u3055\u308c\u305f\u6eb6\u6db2\u306f\u3001\u6f84\u660e\u3067\u7121\u8272\u3001\u76ee\u306b\u898b\u3048\u308b\u7c92\u5b50\u304c\u306a\u3044\u306f\u305a\u3067\u3059\u3002 <strong>\u5b8c\u5168\u306b\u518d\u6eb6\u89e3\u3057\u305f\u6eb6\u6db2\u306f\u3001\u7121\u8272\u900f\u660e\u3067\u3042\u308b\u5fc5\u8981\u304c\u3042\u308a\u307e\u3059\u3002<\/strong> \u6700\u9069\u306a\u5b89\u5b9a\u6027\u306e\u305f\u3081\u30012\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u300130\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u69cb\u6210\u6eb6\u6db2\u3092\u51cd\u7d50\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044 \u2014 \u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306f\u30da\u30d7\u30c1\u30c9\u306e\u5b8c\u5168\u6027\u3092\u52a3\u5316\u3055\u305b\u307e\u3059\u3002\u767d\u6fc1\u3001\u6c88\u6bbf\u3001\u307e\u305f\u306f\u5909\u8272\u304c\u898b\u3089\u308c\u308b\u30d0\u30a4\u30a2\u30eb\u306f\u5ec3\u68c4\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h2 id=\"faqs\">\u3088\u304f\u3042\u308b\u8cea\u554f<\/h2>\n<h3>What is Mazdutide used for in studies?<\/h3>\n<p>Mazdutide is used in studies investigating the dual GLP-1 \/ glucagon receptor co-agonist axis, obesity and body-composition regulation, type 2 diabetes preclinical models, MASLD\/MASH liver disease, energy-expenditure and thermogenesis, and comparative multi-agonist incretin pharmacology against single-agonist GLP-1, dual GLP-1\/GIP (tirzepatide), and triple GLP-1\/GIP\/glucagon (retatrutide) compounds. It is the most-cited Chinese-origin metabolic peptide in current literature. The pharmaceutical-grade mazdutide sold here is <strong>\u3057\u307e\u305b\u3093<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>\u30de\u30ba\u30c7\u30e5\u30c1\u30c9\u306f\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u3068\u3069\u306e\u3088\u3046\u306b\u7570\u306a\u308a\u307e\u3059\u304b\uff1f<\/h3>\n<p>\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u306f\u5358\u4e00\u306eGLP-1\u53d7\u5bb9\u4f53\u30a2\u30b4\u30cb\u30b9\u30c8\u3067\u3059\u3002\u30de\u30ba\u30c7\u30e5\u30c1\u30c9\u306fGLP-1\u306b\u52a0\u3048\u3066\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u4f5c\u52d5\u6027\u3092\u8ffd\u52a0\u3057\u3066\u3044\u307e\u3059\u3002\u8ffd\u52a0\u3055\u308c\u305f\u30b0\u30eb\u30ab\u30b4\u30f3\u6210\u5206\u306f\u3001GLP-1\u5358\u72ec\u30a2\u30b4\u30cb\u30b9\u30c8\u3067\u306f\u751f\u307f\u51fa\u305b\u306a\u3044\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u30e1\u30ab\u30cb\u30ba\u30e0 \u2014 \u5b89\u9759\u6642\u4ee3\u8b1d\u7387\u306e\u5897\u52a0\u3001\u809d\u81d3\u306e\u8102\u8cea\u52d5\u54e1\u3001\u8910\u8272\u8102\u80aa\u306e\u6d3b\u6027\u5316 \u2014 \u306b\u5bc4\u4e0e\u3057\u307e\u3059\u3002\u540c\u7b49\u306e\u30d5\u30a7\u30fc\u30ba3\u8a66\u9a13\u3067\u306f\u3001\u30de\u30ba\u30c7\u30e5\u30c1\u30c9\u306f\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u5358\u72ec\u3088\u308a\u3082\u308f\u305a\u304b\u306b\u5927\u304d\u306a\u4f53\u91cd\u6e1b\u5c11\u52b9\u679c\uff0815\u301c17%\u5bfe\u7d0415%\uff09\u3092\u793a\u3057\u307e\u3059\u304c\u3001\u4e3b\u306a\u5b9f\u969b\u7684\u306a\u9055\u3044\u306f\u4f53\u91cd\u6e1b\u5c11\u306e\u30e1\u30ab\u30cb\u30ba\u30e0\u7684\u6839\u62e0\u3067\u3059\uff1a\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u306f\u4e3b\u306b\u98df\u7269\u6442\u53d6\u306e\u6e1b\u5c11\u3092\u4ecb\u3057\u3066\u3001\u30de\u30ba\u30c7\u30e5\u30c1\u30c9\u306f\u6442\u53d6\u91cf\u306e\u6e1b\u5c11\u3068\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u306e\u5897\u52a0\u306e\u4e21\u65b9\u3092\u901a\u3058\u3066\u4f5c\u7528\u3057\u307e\u3059\u3002 <\/p>\n<h3>\u30de\u30ba\u30c7\u30e5\u30bf\u30a4\u30c9\u306f\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u3068\u3069\u306e\u3088\u3046\u306b\u7570\u306a\u308a\u307e\u3059\u304b\uff1f<\/h3>\n<p>Both are dual incretin agonists, but they activate different second receptors. Tirzepatide is GLP-1 + GIP. Mazdutide is GLP-1 + glucagon. The two receptor combinations produce qualitatively different metabolic profiles: GIP (tirzepatide) adds adipocyte lipolysis under fasting conditions and modest effects on energy expenditure; glucagon (mazdutide) adds substantial energy expenditure and hepatic lipid mobilisation. Tirzepatide has the larger Phase 3 dataset and larger body-weight effect; mazdutide has the unique mechanism for MASLD\/MASH studies given the glucagon-driven hepatic lipid component. <\/p>\n<h3>Mazdutide\u306fRetatrutide\u3068\u3069\u306e\u3088\u3046\u306b\u7570\u306a\u308a\u307e\u3059\u304b\uff1f<\/h3>\n<p>Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). Mazdutide is a dual agonist that shares the GLP-1 + glucagon arms but lacks the GIP component. Retatrutide&#8217;s Phase 2 body-weight effect is larger than mazdutide&#8217;s Phase 3 result, suggesting GIP receptor activation adds substantial benefit on top of GLP-1 + glucagon. For studies isolating the GLP-1 + glucagon combination specifically, mazdutide is the cleaner tool because it avoids the GIP confound; for maximum body-weight effect, retatrutide remains the canonical reference. <\/p>\n<h3>What is the typical Mazdutide dose?<\/h3>\n<p>Published preclinical and clinical studies protocols use weekly subcutaneous dosing with a titration schedule starting at 1.5\u20133\u00a0mg and increasing to maintenance doses of 4\u20139\u00a0mg weekly \u2014 the dose range used in GLORY-1 and DREAMS-1 Phase 3 trials. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 ~1.6\u00a0mL equals a 4\u00a0mg clinical-equivalent dose. <\/p>\n<h3>Mazdutide\u306fFDA\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>No. Mazdutide is not FDA-approved in the United States, nor is it EMA- or MHRA-approved. It has been approved by China&#8217;s NMPA for human use (one of the first dual GLP-1\/glucagon agonists to receive any regulatory approval worldwide), but Western regulatory submission is still pending or ongoing as of current literature. <\/p>\n<h3>Mazdutide\u306f\u3069\u306e\u3088\u3046\u306b\u4fdd\u7ba1\u3059\u308c\u3070\u3088\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\uff1a\u77ed\u671f\u4f7f\u7528\u306e\u4f5c\u696d\u7528\u30b9\u30c8\u30c3\u30af\u306f2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3001\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u5b58\u306f-20\u00b0C\u3067\u4fdd\u7ba1\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u5f8c\u306e\u6eb6\u6db2\uff1a2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u300130\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u5f8c\u306e\u6eb6\u6db2\u306f\u51cd\u7d50\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306b\u3088\u308a\u30da\u30d7\u30c1\u30c9\u304c\u5206\u89e3\u3055\u308c\u307e\u3059\u3002\u5e38\u306b\u76f4\u5c04\u5149\u3092\u907f\u3051\u3066\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h3>Mazdutide\u3092\u3069\u306e\u3088\u3046\u306b\u6eb6\u89e3\u3057\u307e\u3059\u304b\uff1f<\/h3>\n<p>\u4e0a\u8a18\u306e\u6eb6\u89e3\u624b\u9806\u306b\u5f93\u3063\u3066\u304f\u3060\u3055\u3044\u3002\u30d0\u30a4\u30a2\u30eb\u306e\u5074\u58c1\u3092\u4f1d\u308f\u305b\u3066\u9759\u83cc\u6c34\u3092\u52a0\u3048\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u304b\u3051\u306a\u3044\uff09\u3001\u9759\u304b\u306b\u65cb\u56de\u3055\u305b\u3001\u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30675\uff5e10\u5206\u9593\u9759\u7f6e\u3057\u307e\u3059\uff08\u30a2\u30b7\u30eb\u5316\u30da\u30d7\u30c1\u30c9\u306f\u5c0f\u3055\u306a\u672a\u4fee\u98fe\u30da\u30d7\u30c1\u30c9\u3088\u308a\u3082\u6eb6\u89e3\u306b\u6642\u9593\u304c\u304b\u304b\u308a\u307e\u3059\uff09\u3002\u3057 <strong>\u3057\u307e\u305b\u3093<\/strong> \u30d0\u30a4\u30a2\u30eb\u3092\u632f\u3063\u3066\u304f\u3060\u3055\u3044\u3002\u6b63\u3057\u304f\u518d\u6eb6\u89e3\u3055\u308c\u305f\u6eb6\u6db2\u306f\u900f\u660e\u3067\u7121\u8272\u3067\u3059\u30025 mg\u306e\u30d0\u30a4\u30a2\u30eb\u306b2.0 mL\u306e\u5e0c\u91c8\u6db2\u3092\u52a0\u3048\u305f\u5834\u5408\u3001\u4f5c\u696d\u6fc3\u5ea6\u306f2.5 mg\/mL\u3067\u3059\u3002 <\/p>\n<h3>MedsBase\u3067\u306f\u3069\u306e\u5bb9\u91cf\u306e\u30ec\u30bf\u30eb\u30c8\u30eb\u30c1\u30c9\u3092\u53d6\u308a\u63c3\u3048\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>MedsBase carries Mazdutide in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Mazdutide\u304c\u306a\u305c\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u3082\u6d3b\u6027\u5316\u3059\u308b\u306e\u3067\u3059\u304b\uff1f<\/h3>\n<p>Mazdutide\u306e\u69cb\u9020\u7684\u30a4\u30f3\u30b9\u30d4\u30ec\u30fc\u30b7\u30e7\u30f3\u306f\u3001\u8178\u7ba1L\u7d30\u80de\u3067\u30d7\u30ec\u30d7\u30ed\u30b0\u30eb\u30ab\u30b4\u30f3\u304c\u30d7\u30ed\u30bb\u30b7\u30f3\u30b0\u3055\u308c\u3066\u751f\u3058\u308b\u5185\u56e0\u6027\u306e37\u30a2\u30df\u30ce\u9178\u304b\u3089\u306a\u308b\u30aa\u30ad\u30b7\u30f3\u30c8\u30e2\u30b8\u30e5\u30ea\u30f3\u3067\u3042\u308a\u3001\u3053\u308c\u306f\u3082\u3068\u3082\u3068GLP-1\u53d7\u5bb9\u4f53\u3068\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u306e\u4e21\u65b9\u3092\u6d3b\u6027\u5316\u3057\u307e\u3059\u3002\u3057\u305f\u304c\u3063\u3066\u3001\u3053\u306e\u30c7\u30e5\u30a2\u30eb\u85ac\u7406\u4f5c\u7528\u306f\u4eba\u5de5\u7684\u306b\u4f5c\u308a\u51fa\u3055\u308c\u305f\u3082\u306e\u3067\u306f\u306a\u304f\u3001\u5929\u7136\u306e\u30aa\u30ad\u30b7\u30f3\u30c8\u30e2\u30b8\u30e5\u30ea\u30f3\u306e\u9aa8\u683c\u306b\u7531\u6765\u3057\u3066\u3044\u307e\u3059\u3002\u4eba\u5de5\u7684\u306b\u8a2d\u8a08\u3055\u308c\u3066\u3044\u308b\u306e\u306f\u3001DPP-4\u306b\u3088\u308b\u5207\u65ad\u3078\u306e\u8010\u6027\u3068\u3001\u90311\u56de\u306e\u534a\u6e1b\u671f\u3092\u5b9f\u73fe\u3059\u308b\u8102\u80aa\u9178\u30a2\u30b7\u30eb\u5316\u3001\u305d\u3057\u3066\u6b63\u5473\u306e\u8840\u7cd6\u964d\u4e0b\u4f5c\u7528\u3092\u512a\u5148\u3059\u308b\u305f\u3081\u306eGLP-1\u5bfe\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u306e\u6d3b\u6027\u6bd4\u306e\u5fae\u8abf\u6574\u3067\u3059\u3002 <\/p>\n<h3>\u30b0\u30eb\u30ab\u30b4\u30f3\u6210\u5206\u306f\u9ad8\u8840\u7cd6\u3092\u5f15\u304d\u8d77\u3053\u3057\u307e\u3059\u304b\uff1f<\/h3>\n<p>This is the classic &#8220;glucagon paradox&#8221; in dual-agonist studies. Glucagon alone raises glucose by stimulating hepatic glucose output, which would worsen rather than improve diabetes. In mazdutide, the GLP-1 component overrides this through dominant glucose-lowering action on insulin and glucagon-suppression at beta- and alpha-cells, while the glucagon arm preserves the lipid-mobilisation and energy-expenditure benefits. Published studies confirms net glucose-lowering despite glucagon receptor activation, demonstrating that the engineered GLP-1-to-glucagon potency ratio achieves the desired balance. <\/p>\n<h3>Does Mazdutide cause side reported effects?<\/h3>\n<p>\u6700\u3082\u4e00\u8cab\u3057\u305f\u6240\u898b\u306f\u6d88\u5316\u5668\u7cfb\u306e\u75c7\u72b6\u3067\u3042\u308a\u3001\u4ed6\u306eGLP-1\u7cfb\u30da\u30d7\u30c1\u30c9\u3068\u540c\u69d8\u3067\u3059 \u2014 \u5410\u304d\u6c17\u3001\u4e00\u904e\u6027\u306e\u98df\u6b32\u6291\u5236\u3001\u80c3\u6392\u6cc4\u9045\u5ef6\u306f\u7528\u91cf\u4f9d\u5b58\u7684\u3067\u3001\u53d7\u5bb9\u4f53\u306e\u30bf\u30ad\u30d5\u30a3\u30e9\u30ad\u30b7\u30fc\u304c\u751f\u3058\u308b\u305f\u3081\u30014\uff5e8\u9031\u9593\u306e\u7d99\u7d9a\u6295\u4e0e\u306b\u3088\u308a\u6e1b\u5f31\u3059\u308b\u50be\u5411\u304c\u3042\u308a\u307e\u3059\u3002\u30b0\u30eb\u30ab\u30b4\u30f3\u6210\u5206\u306b\u95a2\u9023\u3059\u308b\u6240\u898b\u3068\u3057\u3066\u306f\u3001\u5b89\u9759\u6642\u5fc3\u62cd\u6570\u306e\u8efd\u5ea6\u4e0a\u6607\u3084\uff08\u307e\u308c\u306b\uff09\u4e00\u904e\u6027\u306e\u8840\u5727\u3078\u306e\u5f71\u97ff\u304c\u542b\u307e\u308c\u307e\u3059\u3002\u9577\u671f\u5b89\u5168\u6027\u30c7\u30fc\u30bf\u306f\u3001\u4e2d\u56fd\u306e\u7b2c3\u76f8\u8a66\u9a13\u304a\u3088\u3073\u627f\u8a8d\u5f8c\u8abf\u67fb\u304b\u3089\u5f15\u304d\u7d9a\u304d\u84c4\u7a4d\u3055\u308c\u3066\u3044\u307e\u3059\u3002 <\/p>\n<h3>Mazdutide\u306e\u534a\u6e1b\u671f\u306f\u3069\u306e\u304f\u3089\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>Mazdutide has a plasma half-life sufficient to support once-weekly subcutaneous dosing in clinical studies, achieved through reversible binding to serum albumin via the fatty-acid acyl tether. The exact half-life is somewhat shorter than semaglutide (~165 hours) but in the same once-weekly dosing regime. The dosing schedule and clinical trial design treat it as a fully once-weekly compound. <\/p>\n<h3>How long does Mazdutide take to show effects in preclinical studies?<\/h3>\n<p>\u8010\u7cd6\u80fd\u304a\u3088\u3073\u80c3\u6392\u6cc4\u306b\u5bfe\u3059\u308b\u6025\u6027\u306e\u85ac\u529b\u5b66\u7684\u52b9\u679c\u306f\u3001\u521d\u56de\u6295\u4e0e\u304b\u3089\u6570\u6642\u9593\u4ee5\u5185\u306b\u691c\u51fa\u53ef\u80fd\u3067\u3059\u3002DIO\uff08\u98df\u4e8b\u8a98\u767a\u6027\u80a5\u6e80\uff09\u3052\u3063\u6b6f\u985e\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\u4f53\u91cd\u3078\u306e\u5f71\u97ff\u306f\u3001\u901a\u5e38\u3001\u90311\u56de\u6295\u4e0e\u306e1\uff5e2\u9031\u9593\u5f8c\u306b\u7d71\u8a08\u7684\u306b\u6709\u610f\u306b\u306a\u308a\u30018\uff5e16\u9031\u9593\u304b\u3051\u3066\u5f15\u304d\u7d9a\u304d\u84c4\u7a4d\u3057\u307e\u3059\u3002\u4f53\u7d44\u6210\u306b\u5bfe\u3059\u308b\u6700\u5927\u52b9\u679c\u306f16\uff5e24\u9031\u9593\u306e\u7d99\u7d9a\u6295\u4e0e\u3067\u73fe\u308c\u3001GLORY-1\u8a66\u9a13\u306b\u304a\u3051\u308b\u30d2\u30c8\u7b2c3\u76f8\u306e\u63a8\u79fb\u3092\u53cd\u6620\u3057\u3066\u3044\u307e\u3059\u3002 <\/p>\n<h3>Mazdutide\u306e\u56fd\u969b\u914d\u9001\u3092\u6ce8\u6587\u3067\u304d\u307e\u3059\u304b\uff1f<\/h3>\n<p>Yes. MedsBase ships Mazdutide worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\">\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, Body-Composition, and Multi-Agonist Studies<\/h2>\n<ul>\n<li><a href=\"\/ja\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 \u4e09\u91cdGLP-1\/GIP\/\u30b0\u30eb\u30ab\u30b4\u30f3\u4f5c\u52d5\u85ac \u2014 Mazdutide\u306e\u53d7\u5bb9\u4f53\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u306bGIP\u3092\u8ffd\u52a0<\/li>\n<li><a href=\"\/ja\/tirzepatide\/\"><strong>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/strong><\/a> \u2014 \u30c7\u30e5\u30a2\u30ebGLP-1\/GIP\u4f5c\u52d5\u85ac \u2014 \u30b0\u30eb\u30ab\u30b4\u30f3\u306e\u4ee3\u308f\u308a\u306bGIP\u3092\u7528\u3044\u305f\u4ee3\u66ff\u30c7\u30e5\u30a2\u30eb\u4f5c\u52d5\u85ac\u3067\u3059\u3002<\/li>\n<li><a href=\"\/ja\/semaglutide\/\"><strong>\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/strong><\/a> \u2014 \u5358\u4e00GLP-1\u4f5c\u52d5\u85ac \u2014 \u6a19\u6e96\u7684\u306a\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u6bd4\u8f03\u85ac\u3067\u3059\u3002<\/li>\n<li><a href=\"\/ja\/cagrilintide\/\"><strong>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9<\/strong><\/a> \u2014 \u30a2\u30df\u30ea\u30f3\u985e\u4f3c\u4f53 \u2014 \u4ee3\u66ff\u306e\u4f75\u7528\u85ac\u7406\u5b66\u30a2\u30d7\u30ed\u30fc\u30c1\uff08CagriSema\uff09<\/li>\n<li><a href=\"\/ja\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adiposity<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>\u53c2\u8003\u6587\u732e<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 \u591a\u91cd\u30a2\u30b4\u30cb\u30b9\u30c8\u4ee3\u8b1d\u30da\u30d7\u30c1\u30c9\u306e\u5168\u4f53\u50cf\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/strong><\/p>\n<p style=\"margin: 0;\">\u3059\u3079\u3066\u3092\u95b2\u89a7 <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\"><strong>\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/strong><\/a>, \u3001\u95a2\u9023\u5316\u5408\u7269\u3068\u3057\u3066 <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a> (\u4e09\u91cd\u30a2\u30b4\u30cb\u30b9\u30c8), <a href=\"https:\/\/medsbase.com\/ja\/tirzepatide\/\">\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/a> \uff08\u30c7\u30e5\u30a2\u30ebGLP-1\/GIP\u53d7\u5bb9\u4f53\u4f5c\u52d5\u85ac\uff09\u3001\u304a\u3088\u3073 <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a> \uff08\u5358\u4e00\u53d7\u5bb9\u4f53\u4f5c\u52d5\u85ac\uff09\u3002\u76f4\u63a5\u6bd4\u8f03\u30ac\u30a4\u30c9\uff1a <a href=\"https:\/\/medsbase.com\/ja\/retatrutide-vs-tirzepatide\/\">\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9 vs \u30c1\u30eb\u30bc\u30d1\u30c1\u30c9 \u2014 \u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8 vs \u30c7\u30e5\u30a2\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 GLP-1\uff0b\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u30c7\u30e5\u30a2\u30eb\u5171\u4f5c\u52d5\u85ac<br \/>\n\u2705 \u30aa\u30ad\u30b7\u30f3\u30c8\u30e2\u30b8\u30e5\u30ea\u30f3\u7531\u6765\u306e\u9aa8\u683c\uff08IBI362 \/ LY3305677\uff09<br \/>\n\u2705 GLP-1\u5358\u72ec\u3092\u8d85\u3048\u308b\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u30e1\u30ab\u30cb\u30ba\u30e0\u3092\u8ffd\u52a0<br \/>\n\u2705 \u4e2d\u56fd\u3067\u627f\u8a8d\u6e08\u307f\uff1b\u6b27\u7c73\u3067\u306f\u6cbb\u9a13\u6bb5\u968e<br \/>\n\u2705 \u90311\u56de\u6295\u4e0e<\/p>\n<p><strong>Mazdutide<\/strong> \u5408\u6210\u30da\u30d7\u30c1\u30c9\u5316\u5408\u7269\u3092\u542b\u307f\u307e\u3059\u3002<\/p>","protected":false},"featured_media":70965,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6285,5441],"class_list":["post-70754","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-mazdutide","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product\/70754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/comments?post=70754"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media\/70965"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media?parent=70754"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_brand?post=70754"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_cat?post=70754"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_tag?post=70754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}